finance.yahoo.com ·
Neuropace Q1 Earnings Call Highlights
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedNeuroPace, a medical device company, reported strong Q1 results driven by demand for its RNS System for epilepsy. Revenue growth and guidance raise indicate expanding adoption at Level 4 epilepsy centers. The company is pursuing FDA review for idiopathic generalized epilepsy, which could open a larger market. Impact is company-specific and sector-wide for neuromodulation devices.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- NeuroPace Q1 2026 revenue $22.1M
- Full-year revenue guidance raised to $99M-$101M
- RNS System revenue up 19.5% YoY
- Adjusted EBITDA loss narrowed to $3.3M from $4.1M
- Active prescribers and patient pipeline at all-time highs
Potential FDA label expansion for idiopathic generalized epilepsy suggests flat impact on mid-term revenue for neuromodulation devices; magnitude 2.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- MEDICAL_DEVICESmid